Edaglitazone have a clear PPAR-gamma agonist profile, with predominant PPAR-gamma activity and little PPAR-alpha activity. Edaglitazone was reported to significantly improve insulin sensitivity and enhance the rate of glucose oxidation in both the presence and absence of insulin. Additional studies have shown that edaglitazone affects muscle glucose metabolism by additional mechanisms other than PPAR-gamma activation. Phase I clinical studies have revealed that edaglitazone is well-tolerated and capable of significantly improving glucose homeostasis. Edaglitazone had been in phase II clinical trials for the treatment if type 2 diabetes. However, this research has been discontinued.

Brecanavir (previously known as VX-385), a HIV aspartyl protease inhibitor was developed for the treatment of HIV. The inhibition of HIV viral proteinase enzyme prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. Brecanavir reached Phase II development. However, GlaxoSmithKline announced to discontinue development brecanavir. Because of the inability to develop a viable oral dosage formulation capable of delivering the desired brecanavir levels in patients with multi-drug resistant HIV.

Benzetimide, a muscarinic acetylcholine receptor antagonist that was investigated as an antiparkinson-agent and was studied in the treatment of diarrheas of cattle and calves. Benzetimide is an enantiomer of dexetimide that has been used to treat neuroleptic-induced Parkinsonism.

Feloprentan is an endothelin receptor antagonist.

Metheptazine was studied as an analgesic agent.

Almorexant (ACT-078573) is an orally active dual orexin receptor antagonist that is being developed by Actelion Ltd, in collaboration with GlaxoSmithKline plc, for the treatment of primary insomnia. Almorexant is a first-in-class compound that targets the orexin system, which plays a key role in wake promotion and stabilization; In January 2011, GlaxoSmithKline (GSK) and Actelion Ltd announced that clinical development of Phase III of almorexant has been discontinued. This decision follows a review of data from additional clinical studies, which were conducted to further establish the clinical profile of almorexant, including the tolerability profile.

Diathymosulfone is an antibacterial agent. It was used as antimycobacterial and leprostatic drug.

Diampromide is a synthetic narcotic analgesic. It was designed as a methadone analog and hence with a chiral center similar to that of the parent. Diampromide approximates to the potency of pethidine and morphine in mice and rats, respectively. It has been evaluated in postoperative pain. Diampromide is not found in any pharmaceutical preparations sold in the United States. It is under international control according to the UN Single Convention 1961 and its amendments, Schedule I.

Deximafen is antidepressant drug developed by Abbot Laboratories Inc.